DNER and non-small cell lung carcinoma: Birabresib (previously MK-8628/OTX015) (Merck Sharp and Dohme Corp., Kenilworth, NJ, USA) is an orally administered BET inhibitor.[18,19] An open-label, Phase Ib, 3 + 3 dose-escalation trial of birabresib to determine DLT and recommended Phase II dose began in October 2014 and enrolled 47 patients (one was not treated) with castration-resistant prostate cancer (CRPC), NMC, and non-small cell lung cancer (NSCLC).